title: [Treatment of bone disease in chronic kidney disease and in renal transplant recipients under K/DOQI clinical practice guidelines].
abstract: The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (K/DOQI) provides evidence based clinical practice guidelines developed for all phases of kidney disease and related complications, from diagnosis to monitoring and management. Bone disease sets in during the early stages of Chronic Kidney Disease (CKD). Bone disease is observed in almost patients with chronic renal failure and after renal transplantation. Hyperparathyroid (high turnover) bone disease in patients with chronic renal failure is found most frequently followed by mixed osteodystrophy, low-turn over bone disease, and osteomalasia. Ninety to one hundred percent of kidney transplant patients have histological evidence of osteodystrophy and osteopenia (reduction of bone mass) following renal transplantation. Furthermore, osteoporosis is also appeared in many renal transplant recipients. After renal transplantation, renal osteodystrophy generally improves but bone mineral density (BMD) often worsens. When renal bone disease is assessed using a combination of biochemical markers, histology and bone densitometry, early intervention and carefully effective therapies might be reduced the morbidity associated with these common problems.
authors.affiliation: Department of Urology, Kidney Center, Tokyo Women's Medical University.
authors.forename: Tadahiko
authors.initials: T
authors.lastname: Tokumoto
authors.forename: Kazunari
authors.initials: K
authors.lastname: Tanabe
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Toma
authors.forename: Takashi
authors.initials: T
authors.lastname: Akiba
mesh_terms: D015519:Bone Density; D001851:Bone Diseases, Metabolic / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy*; D002116:Calcitonin / Q000627:therapeutic use; D002908:Chronic Disease; D004164:Diphosphonates / Q000627:therapeutic use; D004852:Epoxy Compounds / Q000627:therapeutic use; D005665:Furosemide / Q000627:therapeutic use; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000209:etiology; D007475:Ion Exchange Resins / Q000627:therapeutic use; D007674:Kidney Diseases / Q000150:complications*; D016030:Kidney Transplantation / Q000009:adverse effects*; D000077268:Pamidronate; D016105:Parathyroidectomy; D010758:Phosphorus / Q000378:metabolism; D016226:Phosphorus, Dietary / Q000008:administration & dosage; D011073:Polyamines; D011095:Polyethylenes / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D006435:Renal Dialysis / Q000009:adverse effects; D000069603:Sevelamer; D013739:Testosterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014481:United States; D014807:Vitamin D / Q000008:administration & dosage; D014808:Vitamin D Deficiency / Q000209:etiology
chemical_list: D004164:Diphosphonates; D004852:Epoxy Compounds; D007475:Ion Exchange Resins; D016226:Phosphorus, Dietary; D011073:Polyamines; D011095:Polyethylenes; D014807:Vitamin D; D010758:Phosphorus; D013739:Testosterone; D005665:Furosemide; D002116:Calcitonin; D000069603:Sevelamer; C016131:testosterone 17 beta-cypionate; D000077268:Pamidronate